Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorhexidine and Povidone Iodine for COVID-19 Viral Load Reduction
NCT04941131Phase 4Completed
- Sponsor
- King Abdulaziz University
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of chlorhexidine and povidone-iodine in coronavirus disease 2019 (COVID-19), sponsored by King Abdulaziz University. Primary endpoint: E Genes at 6 months. Started May 2023; status: completed.
02
Drugs
chlorhexidinepovidone-iodine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04941131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941131.